Details

Autor(en) / Beteiligte

• Giugliano, Robert P., MD, SM, FACC
• Wiviott, Stephen D., MD
• Stone, Peter H., MD, FACC
• Simon, Daniel I., MD, PhD, FACC
• Schweiger, Marc J., MD, FACC
• Bouchard, Alain, MD, FACC
• Leesar, Massoud A., MD, FACC
• Goulder, Michael A., BSc
• Deitcher, Steven R., MD
• McCabe, Carolyn H., BS
• Braunwald, Eugene, MD, MACC

Titel

Recombinant Nematode Anticoagulant Protein c2 in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome

Ist Teil von

• Journal of the American College of Cardiology, 2007-06, Vol.49 (25), p.2398-2407

Ort / Verlag

Elsevier Inc

Erscheinungsjahr

2007

Link zum Volltext

Quelle

EZB Electronic Journals Library

Beschreibungen/Notizen

• Recombinant Nematode Anticoagulant Protein c2 in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome: The ANTHEM–TIMI-32 Trial Robert P. Giugliano, Stephen D. Wiviott, Peter H. Stone, Daniel I. Simon, Marc J. Schweig, Alain Bouchard, Massoud A. Leesar, Michael A. Goulder, Steven R. Deitcher, Carolyn H. McCabe, Eugene Braunwald, for the ANTHEM-TIMI-32 Investigators We evaluated ascending doses of recombinant nematode anticoagulant protein c2 (rNAPc2), a tissue factor/activated factor VII inhibitor in 255 patients with non–ST-segment elevation acute coronary syndrome (nSTE-ACS) and found: 1) a dose-related increase in international normalized ratio and suppression of F1.2; 2) no difference in significant bleeding; and 3) >50% reduction in ischemia by continuous 3-channel electrocardiography with higher-dose rNAPc2 (≥7.5 μg/kg). Procedure-related thrombosis occurred in 5 of 26 patients receiving open-label rNAPc2 without unfractionated heparin, but did not occur if heparin was administered. In patients with nSTE-ACS managed with standard antithrombotics and an early invasive approach, additional proximal inhibition of the coagulation cascade with rNAPc2 is promising, although some heparin may be necessary to avoid procedure-related thrombus formation.